<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABO typing 130</td>
</tr>
<tr>
<td>accountability 248–50</td>
</tr>
<tr>
<td>accreditation status for laboratories 255</td>
</tr>
<tr>
<td>advance care directives 77</td>
</tr>
<tr>
<td>adverse event and reaction reporting 103–4, 247</td>
</tr>
<tr>
<td>affinity, spectrum of 5</td>
</tr>
<tr>
<td>Alder Hey Hospital, Liverpool, UK 13–14, 173</td>
</tr>
<tr>
<td>Algeria 148</td>
</tr>
<tr>
<td>altruism</td>
</tr>
<tr>
<td>donors 14, 70–1, 75</td>
</tr>
<tr>
<td>bone marrow and peripheral blood stem cells 207, 210, 212</td>
</tr>
<tr>
<td>embryos 227–8</td>
</tr>
<tr>
<td>social desirability bias 79</td>
</tr>
<tr>
<td>families of donors 84</td>
</tr>
<tr>
<td>American Association of Blood Banks (AABB) 126</td>
</tr>
<tr>
<td>American Association of Tissue Banks (AATB) 8–9, 169</td>
</tr>
<tr>
<td>consent guidelines 69</td>
</tr>
<tr>
<td>donor history questionnaire 103</td>
</tr>
<tr>
<td>ethical issues 149</td>
</tr>
<tr>
<td>funeral home directors 167, 168</td>
</tr>
<tr>
<td>routine referral 30</td>
</tr>
<tr>
<td>standards 32, 135</td>
</tr>
<tr>
<td>testing requirements 117, 120, 122</td>
</tr>
<tr>
<td>hemodilution 129</td>
</tr>
<tr>
<td>test results, management of 134, 140</td>
</tr>
<tr>
<td>donor notification 141–2, 145, 146</td>
</tr>
<tr>
<td>tissue recovery site, documented evaluation of 170</td>
</tr>
<tr>
<td>American Fertility Society 226</td>
</tr>
<tr>
<td>American Nurses Association 33–4</td>
</tr>
<tr>
<td>American Society of Reproductive Medicine 226, 237</td>
</tr>
<tr>
<td>Anatomy Acts (UK) 11</td>
</tr>
<tr>
<td>Ancient Arabic Order of the Nobles of the Mystic Shrine 7</td>
</tr>
<tr>
<td>animal bites 100</td>
</tr>
<tr>
<td>antibodies, testing for 118</td>
</tr>
<tr>
<td>apheresis 213, 214</td>
</tr>
<tr>
<td>Argentina 24, 154</td>
</tr>
<tr>
<td>aseptic surgical technique 124</td>
</tr>
<tr>
<td>Association of Organ Procurement Organizations (AOPO) 69, 167, 168</td>
</tr>
<tr>
<td>audit, clinical 252–3</td>
</tr>
<tr>
<td>AusCord 217</td>
</tr>
<tr>
<td>Australia</td>
</tr>
<tr>
<td>bereavement support 60</td>
</tr>
<tr>
<td>bone marrow and peripheral blood stem cells donation 207, 211</td>
</tr>
<tr>
<td>Christianity 154</td>
</tr>
<tr>
<td>cord blood donation 203, 204, 217</td>
</tr>
<tr>
<td>donor history 107</td>
</tr>
<tr>
<td>exclusion criteria for donation 101</td>
</tr>
<tr>
<td>explicit/informed consent 23</td>
</tr>
<tr>
<td>Organ Donor Awareness Week 38</td>
</tr>
<tr>
<td>promotion of tissue banking to the public 37, 38</td>
</tr>
</tbody>
</table>
Index 265

regulatory framework 24
routine recovery 29
testing requirements 117, 121
tissue transplant coordinators 158
Australian Bone Marrow Donor Registry (ABMDR) 207, 217
Australian Medical Association 42
Australians Donate 37, 42
Austria 23, 69
autonomy, and consent 67, 71, 76, 93
family autonomy 80, 81
posthumous autonomy 77, 78, 79, 80, 81, 86, 89, 94
Avicenna 153
babesia 127
bacterial contamination, testing for 123–6
Bangladesh 24, 152
Belgium 23, 24, 57, 69
bereavement
staff 182
support 59–64
see also grief
Biomedical Tissue Services, USA 32
Biotechnology and Biological Sciences Research Council (UK) 225
bites, animal 100
Blair, Tony 229
blood samples
deceased donors, sample quality 127–8
future viral testing 120–3
hemodilution 100, 106–7, 116, 128–9
history of donations and blood banks 2–3, 4
labeling 130
bone marrow donation 198–9, 205–6, 212–13, 217–19
equity of access 217–19
history taking 105
information systems and privacy 207–8
long-term protection of donors and recipients 214–15
recruitment 206–7
respect and protection of donors 209–12, 214–15
Brauer, Karl 2
Brazil 24, 154
Breakthrough Collaborative for Organ Donation 19
Bristol Royal Infirmary, UK 173
British Association for Tissue Banking 226
Brown, Gordon 229
Brown, Harry 6
Brown, James Barrett 1, 5
Brown, Louise 224
Buddhism 150–1
Burma 158
Burnett, Sir Macfarlane 5
burnout 183
Bush, George 226
cadaveric donors see deceased donors
Cambodia 150
Canada
adverse event and reaction reporting 103
donor history 107
exclusion criteria for donation 101
explicit/informed consent 23
promotion of tissue banking to the public 38
public awareness and support for tissue donation 36–7
regulatory framework 24–5
routine referral 31
testing requirements 117, 119
Canadian Council for Donation and Transplantation (CCDT) 36, 37, 38
capital punishment 9
Catholicism 154–5
Centers for Disease Control and Prevention (CDC) 103
Central Eye Bank of Iran 153
Chagas’ disease 127, 137
child donors
cord blood 215–16
medical examiners’ and coroners’ concerns 163–4
risk reduction 101–3
Chile 25, 154
China 25, 152, 157–8
Chinese Middleware Documentation
Project 157–8
Christianity 154–5
Circle of Life 36
clinical audit 252–3
clinical governance 243–4, 260–1
accountability 248–50
clinical audit 252–3
continuing professional development 255–6
glossary 261–2
good practice 256
introduction of 244–6
medical direction 257–9
organizational needs for evidence-based decisions 247–8
policy setting in health care 246–7
quality assurance 251
risk assessment and management 253–5
service users, learning from 256–7
standards, use of 250–1
Clinic Hospital/TSF, Barcelona 46–8
cloning 224
competence to consent 71–2
conditioning regimens, hematopoietic stem cell recipients 210
confidentiality
bone marrow and peripheral blood stem cells donation 208, 209, 214
cord blood donation 216
ethics committees 92
history taking 104
information for donor family 89
safeguards 94–5
staff support 193
test results, management of 142, 145, 146
consent 67–8, 95–6
for deceased donation 70–1, 76
confidentiality safeguards 94–5
conflicting preferences among family members 81–2
conflicting preferences between deceased and family 57, 80–1
enabling an informed decision 82–90, 91–2
and grief process 52–4
history of tissue banking 13, 14
realizing donor intent and the future use of tissue 90–4
reasons for giving or refusing consent 56
recruitment for tissue donation 19
skilled and sensitive approach 54–7
by telephone 54–5
who decides and according to what? 76–9
explicit see informed consent
first-person see donor designation
game and embryo donation
best practices 229
conditional consent 232, 234–5
coordination 224–6
informed consent 227–9
UK criteria 230–2
implied see implied/presumed consent
informed see informed consent
intransitivity 72, 86
legal and regulatory frameworks 69–70
from living donors 70
bone marrow and peripheral blood stem cells donation 211, 217
clinical and donation interventions, differences between 70–1
competence and voluntariness 71–2
cord blood donation 199–202, 203, 217
information for 72–5
omitting the recommendation to donate 75–6
opt-in see opt-in consent system
opt-out see opt-out consent system
presumed see implied/presumed consent
for research use of tissue
discarded tissue 146
hematopoietic stem cells 217
surrogate 78
withdrawal of 89
continuing professional development (CPD) 185, 255–6
Cook County Hospital, Chicago 3
cord blood donation 198–9, 217–19
cert consent process 199–202
equity of access 217
ethical and policy issues 216–17
follow-up of donor and recipient 215–16
history taking 105
protections needed
  for maternal and infant donors 204–5
  for recipients 202–4
respect for donors as research subjects 217
corneal donation
  history 2, 3, 4, 9, 10
  history taking, importance of 99
  routine recovery 29
  spectrum of affinity 5
  spiritual beliefs 83
see also eye banks
Corneal Grafting Act (1952, UK) 11
Corneal Tissue Act (1986, UK) 7
coroners and forensic investigators
  as donation stakeholder 33, 34
  facilitating donation 160–5, 174, 175
  history of tissue banking 12
  routine recovery 29
  cosmetic uses of donated tissue 15
  consent issues 72, 86, 90, 93
counseling skills 188, 189
Creutzfeldt–Jakob disease (CJD)
  cadaver transmission 14
  exclusion criteria for donation 102
  gamete and embryo donation 238
  history taking, importance of 99
  risk assessment and management 254–5
  testing 123, 137
Cuba 25, 154
cultural issues 148, 150, 158–9
  ethics 149
see also spirituality and religion
  cultural work 4–5, 9–10, 14
death, circumstances of 106–7
debriefing staff 190–1, 194
deceased donors 20–1
  blood sample quality 127–8
  discarded tissue 146
histories of tissue banking 4, 6, 9, 10, 11–12, 14–15
history, medical and behavioral 109–10
legal and regulatory frameworks for consent 69–70
quarantining tissue 139
staff development and support 194–6
  background 179–83
  organizational, practical, and psychological issues 184–7
  practice 190–4
  practice frameworks 187–90
  testing of tissue samples 127–8, 137–8
  results, management of 135, 136, 141, 142, 143–4
see also consent; facilitating donation; recruitment for donation
dermatomes 5–6
designated donors 77
  authorization for deceased-tissue donation, obtaining 91–2
  families’ wishes 56–7, 80–1
  direct method of tissue banking 2, 10
discarded tissue 139, 141, 146
discriminative donation choices 94
disease transmission, risk of 99–101
see also risk reduction, disease transmission
doctors, donors’
  notification of test results 141, 142, 145–6
  as source of donor history 108
Donaldson, Liam 245
Donate Life America 36, 37, 38, 43
donor cards 23, 77
  history 10, 11
  public awareness and support for tissue donation 36
donor designation 77
  authorization for deceased-tissue donation, obtaining 91–2
  families’ wishes 56–7, 80–1
Donor Recovery Services, USA 32
donor registries 23, 42–3, 77
  public awareness and support for donation 37
donors see deceased donors; living donors
education
for collaboration between organ procurement organizations and tissue banks 45
for healthcare professionals 41–2
for the public 37–9
educational uses of donated tissue 93
Edwards, Robert 223
egg donation 222–3, 238–40
background 223–4
consent
best practices 229
coordination 224–6
informed 227–9
UK criteria 230–2
future 232–8
history taking 105
payment 237
staff issues 229–30
Egypt 148, 152
embalmers
enucleation of eyes from corpses 6
facilitating donation 166
embryo donation 222–3, 238–40
background 223–4
consent
best practices 229
coordination 224–6
informed 227–9
UK criteria 230–2
future 232–8
patient concerns 232, 236–7
payment for 237
staff issues 229–30
empathy 188
equity of access hematopoietic stem cells
donation 217
ethics committees 93
EUROCEP project 42
European Association of Tissue Banks (EATB) 169
consent guidelines 70
Ethical Code 149
testing requirements 117
European Union 169
adverse event and reaction reporting 103
clinical governance
accountability 249, 250
health care policy 247
standards 251
tracking of cell and tissue products 256
consent to donation, legal framework 69
donor history 107
education for healthcare professionals 42
exclusion criteria for donation 101, 102
funeral home directors 171
recruitment for tissue donation 21, 22
referral sources 32
regulatory framework 25
testing requirements 117
Tissues and Cells Directive (TCD)
facilitating donation 171
gamete and embryo donation 229, 230, 234, 238
test results, management of 134
tracking of cell and tissue products 256
evidence-based medicine 247–8
exclusion criteria for donation 101–3
expansion of tissue banking 6–9
explicit consent see informed consent
Eye Bank Association of America (EBAA) 169
consent guidelines 69
routine referral 30
testing requirements 117
European Eye Bank Association (EEBA) 117, 169
Eye-Bank for Sight Restoration, New York 9–10
eye banks
history 3, 6, 7, 9–10, 13
moist storage 3
Sri Lanka 151
see also corneal donation
facilitating donation 160–1, 176–7
funeral home directors 165–71
hospital pathologists 172–5
medical examiners and coroners 161–5
see also recruitment for donation
families of donors 52, 65, 70
bereavement support 59–64
communicating information to 57–9
consent 70–1, 76
confidentiality safeguards 94–5
conflicting preferences among the family 81–2
conflicting preferences between deceased and family 57, 80–1
enabling an informed decision 82–90, 91–2
and grief process 52–4
history of tissue banking 13, 14
informed consent 77
legal and regulatory frameworks 69–70
motives 84–5
realizing donor intent and the future uses of tissue 90–4
reasons for giving or refusing consent 56
recruitment for tissue donation 19
skilled and sensitive approach 54–7
by telephone 54–5
who decides and according to what? 76–9
discarded tissue 146
as donation stakeholder 33, 34, 35–6
donor history 105–11
healthcare professionals, relationships with 39
Muslims 153
recruitment for tissue donation 19, 29, 33, 34, 35–6
test results, management of 135, 136, 137, 139, 141, 142, 143–6
see also staff development and support for deceased donation
Fantus, Bernard 3
fears about tissue donation 38–9
Filatov, Vladimir Petrovich 3, 4
financial incentives for donation 71–2
first-person consent see donor designation
First World War 1
Fisher, Russell 12–13
Flosdorf, Earl 7–8
Food and Drug Administration, USA (US FDA) 135, 169
donor history questionnaire 103
funeral home directors 169
reproductive biomedicine 226, 238
testing requirements 117, 122–3, 127
deceased donors 128
hemodilution 128–9
test results, management of 140, 141
forensic investigators see coroners and forensic investigators
for-profit organizations, donations to 15
consent issues 72, 86, 93
ethical issues 93, 149
France 23, 26
funeral home directors
as donation stakeholder 33, 34, 35
enucleation of eyes from corpses 6
facilitating donation 160–1, 165–71, 175
funeral home recovery programs 31–2
fungl contamination, testing for 123–6
future uses of tissues 90–4
gamete donation see egg donation; sperm donation
general practitioners see doctors, donors’
genetic testing, cord blood donation 203–4
Germany 23, 26, 36, 217
Ghana 148
Gift of Life 18–19, 207
Gillies, Harold 1
Global Organization for Organ Donation 36
GPs see doctors, donors’
grief
common manifestations 53
complicating factors 53
and consent for donation 52–4, 78–84
staff 182
see also bereavement
grief companion program 62
Golgar, Alois 2
Griffith, Frederick N. 13
Health Canada 101
healthcare policy 246–7
healthcare professionals (HCPs) as donation stakeholder 33–4
education 41–2
promotion of tissue banking to the public 37, 39–42
Health Insurance Portability and Accountability Act (USA) 142
Helmreich, R. L. 254
hematopoietic stem cell donation 198–9
history taking 104–5
information for consent 73–4
see also bone marrow donation; cord blood donation; peripheral blood stem cells donation
hemodilution 100, 106–7, 116, 128–9
hepatitis transmission 99, 111
disease notification 143–4
risk reduction
history 101–3
testing 116, 117, 118, 119–20, 121, 128, 135, 137, 139, 140–1
highway patrol referral programs 34–5
Hinduism 151
Hippocratic Oath 149
histories of tissue banking 1–2, 3–5
asking 14–15
cultural work 9–10
expansion of tissue banking 6–9
giving and taking 11–14
organizational work 5–6
prehistory 2–3
history taking
best sources for deceased donors 108–10
bone marrow and peripheral blood stem cell donation 209
cord blood donation 203
for different types of donors 104–7
importance 98–9, 100
investigation requirements 111
who decides donor suitability? 112
by whom? 107–8
HIV
donor notification 143, 144
transmission 14, 99, 106, 109–10
Hong Kong 26
horizon scanning to detect new risks 104
hospital donation programs 32
hospital pathologists 160–1, 172–5
hospital staff see healthcare professionals
HTLV transmission 106
risk reduction 101–3, 118, 119–20, 121–2, 135, 140
Human Embryonic Stem Cell Coordinators (HESCCO, UK) 229, 232
Human Fertilisation and Embryology Act (1990, UK) 225, 230
Human Fertilisation and Embryology Authority (HFEA) 225, 226, 232, 235, 237, 238
Human Fertilisation and Embryology (Research Purposes) Regulations (2001, UK) 225
Human Tissue Act (1961, UK) 12
Human Tissue Act (2004, UK) 14, 15, 69, 171, 173–4, 251
accountability 249
conflicting donation preferences between deceased and family 81
consent criteria 230
hospital pathologists 175
Human Tissue Act (Scotland) (2006) 173–4
Human Tissue Authority (HTA, UK) 134, 139, 173–4, 226
accountability 249
donor family representation on board 257
standards 251
Hyatt, George 6, 8
identifiability of tissues, importance of 109–10, 130
clinical governance 256
embryos 234
implied/presumed consent 23
conflicting preferences between deceased and family 80
deceased donors 78–9
families’ wishes 57
histories of tissue banking 13
legal and regulatory frameworks 69
Slovakia 155
incidence–window period model 119–20
indeterminate test results 139–40
India 26, 149, 151, 152
indirect method of tissue banking 2–3, 10
Indonesia 26, 152, 158
infection
and confidentiality issues 94
exclusion criteria for donation 102
see also disease transmission, risk of;
risk reduction, disease transmission
infectious window period 119
information
for bereaved families 57–9, 82–90
approaching the bereaved 82–5
obtaining the authorization 89–90, 91–2
voluntariness 85–6
for donors and prospective donors 72–5
bone marrow and peripheral blood stem cells donation 209
gamete and embryo donation 230–1, 233
from donors and their families see
history taking
for organizations 246
information systems, bone marrow registries 207–8
informed consent 23
autonomy 67
in clinical practice 68–70
conflicting preferences between the deceased and family 80
deceased donors 76–8
gamete and embryo donation 227–9
legal and regulatory frameworks 69–70
living donors 71, 72–5
cord blood donation 202, 203
International Atomic Energy Agency (IAEA) 38, 69, 151
international distribution of cells and tissues 86
international guidelines on consent to donation 69
International Society of Stem Cell Research 237
Internet
bereavement support 61
donor registries 42
education for healthcare professionals 41
promotion of tissue banking to the public 38, 39
service users’ use of 256
in vitro fertilization (IVF)
future 232
history 223–4
payment to egg donors 237
“surplus” embryos 222–3, 227–8
Iran 26, 152, 153–4
Iranian Tissue Bank (I.T.B.) 153–4
Iraq 152
Ireland, Republic of 23, 173
Iris Fund 7
Islam 152–4
Israel 155–7
Israeli Medical Association 156–7
Italy
consent 23, 26
facilitating donation 164
funeral home directors 171
recruitment for tissue donation 20
referral sources 32
regulatory framework 26
Japan 26, 149, 158
Jewish community 155–7, 207
John Paul II, Pope 154
Jordan 152
Judaism 155–7, 207
J. Walter Thompson Advertising Agency 10
keratoplasty see corneal donation; eye banks
kidney transplants, history of 12
Korea 27, 150, 154, 155, 158
Korean War 8
Kuwait 152
labeling of samples 130
cord blood 204
errors 192–3
Laos 150
<table>
<thead>
<tr>
<th>Lasting Legacies</th>
<th>35</th>
</tr>
</thead>
<tbody>
<tr>
<td>law enforcement, as donation stakeholder</td>
<td>33, 34</td>
</tr>
<tr>
<td>legal frameworks on consent to donation</td>
<td>69</td>
</tr>
<tr>
<td>letters from tissue transplant recipients</td>
<td>61</td>
</tr>
<tr>
<td>Lewis, C. S.</td>
<td>64</td>
</tr>
<tr>
<td>Libya</td>
<td>148</td>
</tr>
<tr>
<td>LifeLine of Ohio</td>
<td>35</td>
</tr>
<tr>
<td>Linderer, Rob</td>
<td>45</td>
</tr>
<tr>
<td>Lions Club International</td>
<td>6, 7</td>
</tr>
<tr>
<td>Lions Doherty Eye &amp; Tissue Transplant Bank</td>
<td>13</td>
</tr>
<tr>
<td>living donors</td>
<td></td>
</tr>
<tr>
<td>altruism</td>
<td>14, 70–1, 75</td>
</tr>
<tr>
<td>bone marrow and peripheral blood stem cells</td>
<td>207, 210, 212</td>
</tr>
<tr>
<td>embryos</td>
<td>227–8</td>
</tr>
<tr>
<td>social desirability bias</td>
<td>79</td>
</tr>
<tr>
<td>consent</td>
<td>70</td>
</tr>
<tr>
<td>clinical and donation interventions, the substantial difference between</td>
<td>70–1</td>
</tr>
<tr>
<td>competence and voluntariness</td>
<td>71–2</td>
</tr>
<tr>
<td>information for</td>
<td>72–5</td>
</tr>
<tr>
<td>legal and regulatory frameworks</td>
<td>69–70</td>
</tr>
<tr>
<td>omitting the recommendation to donate</td>
<td>75–6</td>
</tr>
<tr>
<td>discarded tissue</td>
<td>146</td>
</tr>
<tr>
<td>histories of tissue banking</td>
<td>1, 2, 3, 4, 14–15</td>
</tr>
<tr>
<td>history taking</td>
<td>104–5</td>
</tr>
<tr>
<td>realizing donor intent</td>
<td>90–4</td>
</tr>
<tr>
<td>staff stress</td>
<td>186</td>
</tr>
<tr>
<td>test results, management of</td>
<td>135–6, 139, 141, 142</td>
</tr>
<tr>
<td>see also</td>
<td>bone marrow donation; consent; cord blood donation; egg donation; embryo donation; facilitating donation; peripheral blood stem cells donation; recruitment for donation; sperm donation</td>
</tr>
<tr>
<td>lymphocytic choriomeningitis virus (LCMV)</td>
<td>100</td>
</tr>
<tr>
<td>malaria</td>
<td>14, 127</td>
</tr>
<tr>
<td>Malaysia</td>
<td>27, 149, 151, 152, 158</td>
</tr>
<tr>
<td>malignant diseases</td>
<td>102</td>
</tr>
<tr>
<td>mandated choice</td>
<td>57, 69</td>
</tr>
<tr>
<td>mass media</td>
<td>36, 206, 209</td>
</tr>
<tr>
<td>McIndoe, Archibald</td>
<td>10, 11</td>
</tr>
<tr>
<td>McNeil, Robert</td>
<td>13</td>
</tr>
<tr>
<td>Medawar, Peter</td>
<td>5, 7, 15</td>
</tr>
<tr>
<td>media</td>
<td>36, 206, 209</td>
</tr>
<tr>
<td>medical direction and clinical governance</td>
<td>257–9</td>
</tr>
<tr>
<td>medical directors, roles</td>
<td>257–9</td>
</tr>
<tr>
<td>medical examiners</td>
<td></td>
</tr>
<tr>
<td>as donation stakeholder</td>
<td>33, 34</td>
</tr>
<tr>
<td>facilitating donation</td>
<td>160–5</td>
</tr>
<tr>
<td>history of tissue banking</td>
<td>12</td>
</tr>
<tr>
<td>routine recovery</td>
<td>29</td>
</tr>
<tr>
<td>Medical Examiner’s Law (Maryland)</td>
<td>13</td>
</tr>
<tr>
<td>Medical Eye Bank of Maryland (MEB)</td>
<td>13</td>
</tr>
<tr>
<td>Medical Healthcare Products Regulatory Agency (UK)</td>
<td>226</td>
</tr>
<tr>
<td>medical record reviews</td>
<td>40</td>
</tr>
<tr>
<td>Medical Research Council (MRC, UK)</td>
<td>225, 229</td>
</tr>
<tr>
<td>meningoencephalitis</td>
<td>100</td>
</tr>
<tr>
<td>Mexico</td>
<td>27, 154</td>
</tr>
<tr>
<td>microbial contamination, testing for</td>
<td>123–6</td>
</tr>
<tr>
<td>Midwest Transplant Networks, Kansas City</td>
<td>45</td>
</tr>
<tr>
<td>Ministry of Health, Israel</td>
<td>156–7</td>
</tr>
<tr>
<td>mourning</td>
<td>see bereavement; grief</td>
</tr>
<tr>
<td>Muslim community</td>
<td>152–4</td>
</tr>
<tr>
<td>mutilation, fear of</td>
<td>82–3</td>
</tr>
<tr>
<td>Myanmar</td>
<td>158</td>
</tr>
<tr>
<td>myths about tissue donation</td>
<td>38–9</td>
</tr>
<tr>
<td>National Academy of Science (USA)</td>
<td>226, 237</td>
</tr>
<tr>
<td>National Association of Medical Examiners (USA)</td>
<td>164</td>
</tr>
<tr>
<td>National Blood Service (NBS, UK)</td>
<td>15, 135, 142, 145, 191, 226, 238</td>
</tr>
<tr>
<td>continuing professional development</td>
<td>255–6</td>
</tr>
<tr>
<td>Tissue Service (NBS TS)</td>
<td>134, 136, 137, 138, 139, 141, 146</td>
</tr>
</tbody>
</table>
National Donor Family Council (USA) 95
confidentiality issues 95
consent issues 70, 94, 95
National Funeral Directors Association
(NFDA, USA) 167, 168, 169, 170
National Health Service (NHS, UK)
Blood and Transplant 134, 226
Blood Service see National Blood
Service
clinical governance 245, 248, 254
donor registry 42
history of tissue banking 7, 8, 12, 15
routine referral 30
Tissue Services 171, 175, 191
National Institute for Biological
Standards and Control (NIBSC,
UK) 225, 226
National Institute for Health and Clinical
Excellence (NICE, UK) 226, 248
National Kidney Foundation 70
National Patient Safety Agency (NPSA,
UK) 254, 257
National Reporting Learning System
(UK) 254
National Skin Bank (Jerusalem) 157
National University Hospital Tissue Bank
(Singapore) 150–1
Navy Tissue Bank, USA 6, 7, 8
NetCord-FACT 203, 205
Netherlands 27, 30, 43, 69
neurological disease 99, 102
newborns, testing of 129
newspaper announcements of donation 36
New York State Nurses Association
(NYSNA) 34, 41
New Zealand 37
next of kin see families of donors
Nicholas Green Foundation 41
Nigeria 148
Northwest Tissue Center, Seattle 34–5
nucleic acid testing (NAT) 116, 119–20,
122, 128, 135
reliability 121, 128

obituaries 36
opt-in consent system 23
conflicting preferences between
deceased and family 80
deceased donors 76–8
legal and regulatory frameworks 69
opt-out consent system 23
conflicting preferences between
deceased and family 80
deceased donors 78–9
legal and regulatory frameworks 69
Slovakia 155
organ and tissue donation (OTD)
committees 18, 19
organizational work 4, 5–6, 14
Organ Donation Act (1998, Netherlands)
164
organ procurement organizations (OPOs)
collaboration with tissue banks 43–6
recruitment for tissue donation 18, 19,
43–6
organ transplant team
collaboration with tissue banks 43–6
recruitment for tissue donation 18, 19,
43–6
organ transplant team
concerns over consent rates 43–4
as donation stakeholder 33, 34
Padgett, Earl C., Senior 5
Pakistan 152
Patel, Lord Naren 226
pathologists 160–1, 172–5
Paton, R. Townley 9–10
performance goals 40
performance monitoring 40
peripheral blood stem cells donation
205–6, 213–14, 217–19
equity of access 217
ethical and policy issues 216–17
history taking 105
information systems and privacy
207–8
long-term protection of donors and
recipients 214–15
recruitment 206–7
respect and protection of donors 209–
12, 214–15
as research subjects 217
Peru 27
Peter Brent Brigham Hospital, Boston 12
Philippines 27, 154–5
physical examination of donor 108–9
physicians see doctors, donors’
pituitary glands, history of tissue
donation 13
Poland 23
policy setting in health care 246–7
polymerase chain reaction (PCR) 119, 126
nucleic acid testing 120, 128
Pope John Paul II 154
Portugal 23
postmortem examination of donor 109
prehistoric age of tissue banking 2–3
presumed consent see implied/presumed
consent
primary health care standards 158
prion diseases, transmission of 100, 102, 123
see also Creutzfeldt–Jakob disease
privacy issues 94
bone marrow and peripheral blood
stem cells donation 207–8, 214
cord blood donation 205
private cord blood banks 200–1
processing of tissues 15
costs associated with 149
risk reduction for disease transmission
116–17, 126
procurator fiscal 161
professional guidelines on consent 69–70
public
awareness and support for tissue
donation 36–7
as donation stakeholder 33, 34
promotion of tissue banking to the
37–42
quality assurance (QA) 247, 251
quality control 251
quality improvement
philosophy 245
standards 250
quality leadership culture 245–6
quarantine 128–9, 138–9
Queen Victoria Hospital, East Grinstead,
UK 10–11
rabies 100
Reason, Jim 253
recipients of tissues
confidentiality issues 94–5
information for donor families 95
recognition of healthcare professionals
41
recovery of tissue 123–5
bone marrow 212
cord blood 202, 205
corneas 29
funeral home directors’ concerns 168,
170
medical examiners’ and coroners’
concerns 162–3
peripheral blood stem cells 213–14
recruitment for donation 18–23, 48–9
bone marrow and peripheral blood
stem cells 206–7
cases 19–20, 29–30, 31, 34–5, 46–8
Clinic Hospital/TSF, Barcelona, Spain
46–8
collaboration between organ
procurement organizations and
tissue banks 43–6
donor registries 42–3
promotion of tissue banking 37–42
public awareness and support 36–7
public policies 23–31
referral sources 31–2
stakeholders 32–6
see also facilitating donation
Red Cross, American 8
Reese dermatome 5–6
referral sources 31–2
referral systems 29–31
refusals to donate 47
religion see spirituality and religion
remembrance events 61
reproductive setting see egg donation;
embryo donation; sperm donation
required request 29–30
research, donation for 20–1
consent issues 90, 93, 146, 217
discarded tissue 146
egg sharing 237
embryos 223, 227–8, 233
hematopoietic stem cells 217
risk assessment 253–5
risk management 254–5
risk of disease transmission 99–101
risk reduction, disease transmission
98–9, 112–14
donor information requirements 101–3
emerging diseases and horizon scanning 103–4
history taking
best source for deceased donors 108–10
for different types of donors 104–7
investigation requirements 111
who decides donor suitability? 112
by whom? 107–8
testing see testing
tissue processing 116–17
Roman Catholicism 154–5
routine recovery 29
routine referral 30–1
Royal Liverpool Children’s Hospital, UK 13–14, 173, 227
Rycroft, Benjamin 10

Saudi Arabia 152
Scally, Gerald 245
scandals 13, 14
Scottish National Blood Transfusion Service 134
screening see testing
Second World War 7, 8, 10
self-care, staff 183
seronegative infectious window period 119
service users, learning from 256–7
Silva, Hudson 151
sharing of test results 140
Singapore
processing costs 149
regulatory framework 28
religions 150–1, 152, 154
tissue transplant coordinators 158
Sittser, Jerry 64
skin grafts
history 1, 5
spectrum of affinity 5
Skilfiosovsky Institute, Moscow 3, 9
Slovak Center for Organ Donations 155
Slovakia 23, 155
South Africa 148
Soviet Union 3, 9

Spain
consent 23, 69
donation model 20
referral sources 32
regulatory framework 28, 69
transplant coordinators 161
Spanish Civil War 2–3
spectrum of affinity 5
sperm donation
background 223–4
consent
best practices 229
coordination 224–6
informed 227–9
UK criteria 230–2
future 232–8
history taking 105
staff issues 229–30
spirituality and religion 150
Buddhism 150–1
Christianity 154–5
families of donors 63–4, 82–3
Hinduism 151
Islam 152–4
Judaism 155–7, 207
Sri Lanka
processing costs 149
regulatory framework 28
religions 150, 151
tissue transplant coordinators 158
Sri Lanka Eye Donation Society 151
staff development and support for deceased donation 194–6
background 179–83
organizational, practical, and psychological issues 184–7
practice 190–4
practice framework 187–90
stakeholders in donation 32–6
Stalin, Joseph 9
standards 250–1
primary health care 158
Stem Cell Bank (UK) 225–6, 230, 231, 232, 236, 238
Steptoe, Patrick 223
Stockholm syndrome 182
Stockwell, Steve 35
stored blood samples for future viral testing 120–7
stress
  donors 212
  staff 180, 181, 182
  alleviation 185
  increased levels of 186
  sources 183, 186–7
sudden infant death syndrome 164, 193–4
syphilis (Treponema pallidum) 118, 122–3, 135, 139, 140–1
donor notification 143
Tang LuShuYi 157
team-building strategies 191
teamwork, interdisciplinary 245–6
telecare 54
telephone
  consent process undertaken by 54–5, 90, 91
  information given over the 186
  testing 116–17, 130–1
  bone marrow and peripheral blood stem cells donation 209
  cord blood donation 203–4
gamete and embryo donation 238
  hemodilution of donor blood sample 128–9
  incidence–window period model 119–20
  nature of 137–8
  newborns 129
  nucleic acid testing, importance of 119
  quality of deceased-donor blood samples 127–8
  rationale 117–18
  results see test results, management of sample and donor identification issues 130
  seronegative infectious window period 119
  stored blood samples for future viral testing 120–7
viral 118–19
  stored blood samples 120–7
test results, management of 134–7, 147
  discarded tissue 146
donor notification 141–6
  interpretation of results 138–41
  nature of screening tests 137–8
Thailand 150
  Therapeutic Goods Administration (TGA, Australia) 101, 117, 121
  Thomas, Tudor 2
  tissue transplant coordinators 158
  Tissue Services (UK) 171, 175, 191
  traceability of tissues, importance of 109–10, 130
  clinical governance 256
  embryos 234
  transcription-mediated amplification (TMA) 119, 126
  nucleic acid testing 120, 128
  transmissible spongiform encephalopathies (TSEs) 123
trephines 5
  Treponema pallidum (syphilis) 118, 122–3, 135, 139, 140–1
donor notification 143
  Trillium Gift of Life Network 31
  Trypanosoma cruzi 127
tuberculosis 104, 126
UK Transplant 37
  Uniform Anatomical Gift Act (1968, UAGA, USA) 11–12
  Uniform Anatomical Gift Act (2006, UAGA, USA) 23, 69
  conflicting donation preferences between deceased and family 80
  facilitating donation 164
  surrogate consent 80
  withdrawal of consent 89
Union of Soviet Socialist Republics 3, 9
United Arab Emirates 152
United Kingdom
  bereavement support 60
  clinical governance 243, 244, 245
  accountability 249, 250
  clinical audit 252
  evidence-based medicine 248
  policy setting in health care 246
  risk management 254
  service users, learning from 257
  standards 251
| Code of Practice for Tissue Banking | 117 |
| conflicting donation preferences | 81 |
| between deceased and family | 81 |
| consent | 23, 69 |
| cord blood donation | 217 |
| coroners | 161, 174 |
| dedicated donation facility | 171 |
| families’ wishes | 57 |
| gamete and embryo donation | 217 |
| best consenting practices | 229 |
| conditional consent | 235 |
| coordination and consent | 224–6 |
| criteria for consent | 230–2 |
| donor screening | 238 |
| history of tissue banking | 7, 8, 10–11, 12, 13–14, 15 |
| hospital pathologists | 172 |
| in vitro fertilization | 223 |
| promotion of tissue banking to the public | 37 |
| regulatory framework | 25, 69 |
| staff development and support | 180, 191 |
| testing requirements | 117, 121 |
| test results, management of | 134, 135, 136, 138 |
| donor notification | 141, 145 |
| interpretation | 139, 141 |
| voluntary referral | 30 |
| United States Food and Drug Administration | see Food and Drug Administration, USA |
| United States Navy Tissue Bank | 6, 7, 8 |
| United States of America | 34–5 |
| adverse event and reaction reporting | 103 |
| bereavement support | 60, 61 |
| bone marrow and peripheral blood stem cells donation | 207 |
| Christianity | 154 |
| clinical governance | 243, 244 |
| evidence-based medicine | 248 |
| policy setting in health care | 247 |
| risk management | 254 |
| confidentiality issues | 89 |
| conflicting donation preferences | 80, 81 |
| between family members | 81 |
| consent | 23, 29, 69 |
| withdrawal | 89 |
| controversial practices, providing material information about | 86 |
| cord blood donation | 217 |
| coroners | 161, 163, 164 |
| donor history | 103, 107 |
| donor registries | 43 |
| exclusion criteria for donation | 101 |
| for-profit tissue banks | 149 |
| funeral home directors | 167, 168, 169, 170 |
| highway patrol referral programs | 34–5 |
| history of tissue banking | 6–10, 11–13, 14, 15 |
| hospital pathologists | 172 |
| medical examiners | 161, 162, 163, 164 |
| National Donate Life Month | 38 |
| promotion of tissue banking to the public | 37, 38 |
| public awareness and support for donation | 37 |
| recruitment for tissue donation | 18–19, 21, 29–32, 34–5, 37, 38, 43 |
| referral sources | 31–2, 34–5 |
| regulatory framework | 28, 69 |
| reproductive biomedicine | 225, 226, 237, 238 |
| required request | 29–30 |
| routine recovery | 29 |
| routine referral | 30–1 |
| staff development and support | 180, 191 |
| surrogate consent | 80 |
| testing requirements | 117, 119, 122–3, 127, 137 |
| deceased donors | 128 |
| hemodilution | 128–9 |
| test results, management of | 134, 135, 136, 138 |
| donor notification | 141–2, 145–6 |
| information sharing | 140 |
| interpretation | 139, 140, 141 |
| tissue transplant coordinators | 158 |
| West Nile virus | 127 |
| withdrawal of consent | 89 |
variant Creutzfeldt–Jakob disease (vCJD)
cadaver transmission 14
exclusion criteria for donation 102
gamete and embryo donation 238
history taking, importance of 99
risk assessment and management 254–5
Vietnam 28, 150
Vietnam War 8
viral testing 118–19
future 120–3
newborns 129
voluntariness of consent to donation
families of donors 85–6
living donors 71–2
  bone marrow and peripheral blood
  stem cells 210
voluntary referral 30
Von Hippel, Eugene 5
war, and histories of tissue banking 1,
  2–3, 7, 8
Warnock, Mary 224
Washington State Patrol (WSP) 34–5
West Nile virus (WNV) 100, 127
testing for 119, 127, 135, 137
World Health Organization (WHO) 69
World Marrow Donor Association (WMDA) 199, 212, 215
World War I 1
World War II 7, 8, 10
Zambia 148
Zirm, Eduard 2